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Gaucher’s disease or Gaucher is a sphingolipid in which glucocerebroside 
(glucosylceramide) accumulates in cells and certain organs. The disorder 
is characterized by bruising, fatigue, anemia, low blood platelet count and 
enlargement of the liver and spleen, and is caused by deficiency of the enzyme 
glucocerebrosidase.
Most patients with Gaucher disease have radiologic evidence of skeletal 
involvement, including an Erlenmeyer flask deformity of the distal femur, which 
is an early skeletal change. Clinically apparent bony involvement, which occurs 
in more than 20% of patients with Gaucher disease, can present as bone pain 
or pathologic fractures. In patients with symptomatic bone disease, lytic lesions 
can develop in the long bones, ribs, and pelvis, and osteosclerosis or osteopenia 
may be evident at an early age. Bone crises with severe pain and swelling can 
occur in individuals with type 1 Gaucher disease and are frequently mistaken for 
synovitis or osteomyelitis until other symptoms become apparent.
Occasional patients with type 1 Gaucher disease develop pulmonary 
involvement, parkinsonism, or portal hypertension. Patients with milder 
presentations of Gaucher disease are diagnosed later in life during evaluations 
for hematologic or skeletal problems or are found to have splenomegaly during 
routine examinations. Some patients are overtly asymptomatic, and a diagnosis 
is made incidentally after evaluation for other medical problems. Because some 
of the signs and symptoms associated with Gaucher disease are similar to those 
of other more common disorders, it may take months or even years for people 
with Gaucher disease to get an accurate diagnosis. For example, joint pain may 
be attributed to arthritis, or bone pain in the upper legs may be attributed to 
‘growing pains.’ Low red blood cell or platelet count may at first be diagnosed as 
a blood disorder or lead to a work up for leukemia or lymphoma. Also, since the 
initial signs and symptoms may seem rather harmless, patients and physicians 
may not suspect a progressive disease for a long time.
Accurate and definitive diagnosis of Gaucher disease can be made with a simple 
blood test (or assay) that measures glucocerebrosidase enzyme activity. The 
blood sample can be taken in the physician’s office, but may need to be sent to 
a specialized medical center for analysis. In healthy individuals, the test shows 
white blood cells that contain normal enzyme activity; in individuals with 
Gaucher disease, enzyme activity is much lower.
Alternatively, the physician may obtain a skin sample, as certain skin cells called 
fibroblasts can be used to measure glucocerebrosidase activity levels.
A bone marrow biopsy is often taken when a physician suspects a blood cancer, 
such as leukemia. This bone marrow sample may be used to check for Gaucher 
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DNA testing, however, provides the most reliable means 
of identifying carriers. Testing is recommended for all 
first-degree relatives of a confirmed Gaucher disease 
patient. Besides the diagnostic and carrier testing, 
other evaluations are recommended to gauge disease 
progression and tailor therapy. These include skeletal 
imaging, hematological assays, and visceral evaluations. 
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cells. The cells are then viewed under a microscope. 
However, the definitive testing method for Gaucher 
disease continues to be a simple blood test (or enzyme 
assay) that measures enzyme activity.
Blood tests that can show a variety of abnormalities 
such as low red blood cell or low platelet counts, signs 
of chronic inflammation, or of some liver dysfunction. 
X-rays, magnetic resonance imaging (MRI), or 
computerized tomography (CT or “CAT” scans), may 
show abnormalities in bone. MRI or CT scan measures the 
liver and spleen sizes. X-rays and/or electrocardiogram 
(ECG) or other tests to assess whether the lungs and/
or heart are involved may be helpful. Special tests to 
evaluate possible effects on the brain or peripheral 
nerves are also available.
Gaucher disease testing should be considered for anyone 
with Gaucher symptoms, especially delayed growth, 
general weakness, enlarged spleen or liver, anemia, 
bone pain, or spontaneous (pathologic) fractures. Also, 
close family members of an individual with Gaucher 
disease must be tested to determine if they are carriers. 
So evaluation of the complex signs and symptoms can 
be helpful for early diagnosis. On the other hand, several 
tests are available for confirmation of the diagnosis of 
Gaucher disease. In the past, invasive bone-marrow tests 
were most common. Due to the overlap in presentation 
between Gaucher and hematological malignancies, bone 
marrow histology is still frequently done in Gaucher 
patients. Today, measurement of ß-glucocerebrosidase 
activity can be used to measure glucocerebrosidase 
activity in cells obtained from the patient, providing 
a definitive diagnosis of Gaucher disease: enzyme 
activity of 30% or less than normal definitively indicates 
Gaucher disease. Enzyme activity can be measured 
either in leukocytes, which are fairly easily obtained 
from peripheral blood, or in skin fibroblasts, e.g., grown 
from skin biopsies.
DNA testing can be used to aid diagnosis or screen 
for carrier status. In individuals of Eastern European 
ancestry, four specific gene mutations occur in 89% 
to 96% of Gaucher disease patients. This method is 
considered less sensitive than enzyme analysis when 
used as a diagnostic tool in the general population.
